Jagsonpal Pharmaceuticals: Subsequent to fulfilment of the Conditions Precedent under the BTA the transactions has been consummated…
Jagsonpal Pharmaceuticals (JAGSNPHARM) filed a disclosure titled "Subsequent to fulfilment of the Conditions Precedent under the BTA the transactions has been consummated with effect from today i.e. October 01, 2026". The company is valued at about ₹1,545…
What happened
Jagsonpal Pharmaceuticals (JAGSNPHARM) filed a disclosure with the exchanges on 1 October 2026 at 04:57 PM titled "Subsequent to fulfilment of the Conditions Precedent under the BTA the transactions has been consummated with effect from today i.e. October 01, 2026".
Company snapshot
Jagsonpal Pharmaceuticals is a small-cap company, with a market value of about ₹1,545 crore.
The stock last traded at ₹234.7, against a 52-week range of ₹155–₹264.5 (11.3% below the high).
Before this filing the shares had moved −2.5% over the month and −0.1% over three months. Average daily turnover over the last 20 sessions was about ₹13.9 crore.
Promoters held 69.05% at the end of Q1 FY27, down 0.31% points from the previous quarter. Foreign institutions owned 2.30% and domestic institutions 0.62%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 76 | 10.8 | 1.6 |
| Q2 FY26 | 74 | 12.6 | 1.88 |
| Q3 FY26 | 73 | 11 | 1.67 |
| Q4 FY26 | 64 | 8.8 | 1.25 |
| Q1 FY27 | 82 | 13.2 | 2 |
What history shows
This is not the company's first m&a disclosure: BCEIE has 3 earlier filings of this kind on record since May 2026.
After those filings, the stock gained 7.4% on average the next trading day (2 filings with price data).
Market-wide, 1,931 m&a filings with an impact score of 50 or more saw an average next-day move of +0.4%, with 50% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 23 Sept 2026 | A press release dated September 23, 2026, titled "Press Release on… | +7.4% | — |
| 23 Sept 2026 | Acquisition of Wellness Portfolio of Group Pharmaceuticals Limited. | +7.4% | — |
What to watch
- Regulatory approvals, completion of the deal and its effect on revenue and margins.
In the news
Recent coverage elsewhere (links open the original publisher):
- Jagsonpal Pharmaceuticals to Acquire Group Pharma Wellness Portfolio
- Jagsonpal Pharmaceuticals vs Nifty 50: Returns Compared
- Jagsonpal Pharmaceuticals to acquire wellness portfolio of Group Pharmaceuticals
- Jagsonpal Pharmaceuticals acquires Wellness Portfolio for up to ₹46.7 crore
- Jagsonpal Pharmaceuticals flies on executing BTA to acquire Group Pharma`s wellness portfolio
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.